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Abstract
Background: Human sperm protein 17 (Sp17) is a highly conserved protein that was originally isolated from a
rabbit epididymal sperm membrane and testis membrane pellet. It has recently been included in the cancer/testis
(CT) antigen family, and shown to be expressed in multiple myeloma and ovarian cancer. We investigated its
immunolocalisation in specimens of nervous system (NS) malignancies, in order to establish its usefulness as a
target for tumour-vaccine strategies.
Methods: The expression of Sp17 was assessed by means of a standardised immunohistochemical procedure
[(mAb/antigen) MF1/Sp17] in formalin-fixed and paraffin embedded surgical specimens of NS malignancies,
including 28 neuroectodermal primary tumours (6 astrocytomas, 16 glioblastoma multiforme, 5
oligodendrogliomas, and 1 ependymoma), 25 meningeal tumours, and five peripheral nerve sheath tumours (4
schwannomas, and 1 neurofibroma),.
Results:  A number of neuroectodermal (21%) and meningeal tumours (4%) were found heterogeneously
immunopositive for Sp17. None of the peripheral nerve sheath tumours was immunopositive for Sp17. The
expression pattern was heterogeneous in all of the positive samples, and did not correlate with the degree of
malignancy.
Conclusion: The frequency of expression and non-uniform cell distribution of Sp17 suggest that it cannot be
used as a unique immunotherapeutic target in NS cancer. However, our results do show the immunolocalisation
of Sp17 in a proportion of NS tumour cells, but not in their non-pathological counterparts. The emerging complex
function of Sp17 makes further studies necessary to clarify the link between it and immunopositive cells.
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Background
Brain and other nervous system (NS) tumours are a group
of neoplasms that vary in terms of their site of origin, mor-
phological features, genetic alterations, growth potential,
invasiveness, tendency to progression and recurrence, and
response to treatments [1-4]. Their still highly unfavoura-
ble prognosis underlines the need for new therapeutic
approaches, one of the most attractive of which is targeted
immunotherapy (any approach aimed at mobilising or
manipulating a patient's immune system to treat or cure
disease), which is widely considered to be more specific
and less toxic than conventional surgery, chemotherapy
or radiation therapy [5,6]. However, although the blood-
brain barrier and the claimed immunological privilege of
the brain are not necessarily obstacles to effective brain
immunotherapy, these strategies are currently limited by
the paucity of cloned NS target antigens and the fact that
our understanding of anti-tumour immune responses in
the NS is frequently extrapolated from other tissues hav-
ing little in common with it [7,8].
A cancer-testis (CT) family of tumour-associated antigens
has been identified and their encoding genes extensively
investigated [9-13]. Their immunogenicity and restricted
expression in normal tissues makes them ideal molecules
for immunotherapeutic procedures [9,10].
Sperm protein 17 (Sp17) has recently been entitled as
novel CT in ovarian cancer, multiple myeloma and other
blood malignancies [14-16], and mRNA encoding Sp17
has been found in two myeloma cell lines, 17% of a series
of patients with multiple myeloma, and in primary
tumour cells from 70% of a series of patients with ovarian
carcinoma [14,15]. At protein level, Sp17 has been found
in human germinal cells of the testis other than spermato-
gonia [17], as well as in the ciliated epithelia of the respi-
ratory airways and both male and female reproductive
systems [18]. It has also recently been identified in the
synoviocytes of females with rheumatoid arthritis [19],
and in the melanophages of cutaneous melanocytic
lesions [20]. Although these findings have all raised the
question as to whether Sp17 may be a useful target for
tumour immunotherapy [21-23], they also highlight the
fact that its tissue distribution in humans is more complex
than originally thought.
The expression frequencies of many CT antigens have
been determined in a variety of neoplasms [11], but little
is known about their expression in human NS tumours.
The aim of this immunohistochemical study was to inves-
tigate the frequency of Sp17 expression at protein level
and its cell pattern distribution in various histological
subtypes of human NS tumours, including neuroectoder-
mal, meningeal and nerve sheath lesions.
Methods
Patients
The study was conducted in accordance with the guide-
lines of the Ethics Committee of the hospital treating the
patients (Istituto Clinico Humanitas, Rozzano, Milan,
Italy), all of whom were fully informed of the possible dis-
comfort and risks of surgical treatment.
All of the analysed tissues were taken from patients admit-
ted to the Istituto Clinico Humanitas, Rozzano, Milan,
between 2002 and 2004. The patients' mean age was 58
years (range: 18–79), and the group consisted of 26 males
and 32 females.
Tissue specimens
The NS tumour specimens represented 28 neuroectoder-
mal tumours (6 astrocytomas, 16 glioblastomas, 5 oli-
godendrogliomas, and 1 ependymoma), 25 meningeal
tumours, and five nerve sheath tumours (4 schwannomas,
1 neurofibroma).
To evaluate whether Sp17 is expressed at protein level in
non-pathological NS tissue, three further specimens were
taken from one male and two female patients (mean age
58 ± 15 years) who underwent surgical resection for neo-
plastic disease and were sampled at the periphery of the
lesions. The absence of cell or tissue pathologies was sub-
sequently confirmed by microscopy.
All of the specimens were fixed in 10% neutral buffered
formalin (~12 hours) and embedded in paraffin.
Reverse transcription-polymerase chain reaction (RT-
PCR) amplification of Sp17 mRNA
A panel of normal tissue total RNA was obtained from
Strategene Corp. (La Jolla, CA). All of the RNAs were first
treated with DNAse I (Ambion, Austin, TX) to remove
genomic DNA contamination, and first- strand cDNA was
synthesised from 1 µg by means of random hexamer
primers. The primers for 5' Sp17 PCR was 5'-GGCAGT-
TCTTACCAAGAAGAT-3', and that for 3' Sp17 PCR was 5'-
GGAGGTAAAACCAGTGTCCTC-3', both of which
amplify a complementary DNA (cDNA) of approximately
500 base-pairs. PCR was performed by means of 35 ampli-
fication cycles at an annealing temperature of 55°C. The
positive control amplification contained a plasmid with
the Sp17 cDNA and a negative control of the PCR reaction
mixture except for the substitution of cDNA by water.
RNA integrity in each sample was checked by amplifying
a β-actin gene segment. The successful removal of DNA
contamination was confirmed by amplifying the RNA in
each sample without the reverse transcription reaction.
The PCR products were visualised on an ethidium bro-
mide agarose gel for a DNA band of the expected size. AllBMC Cancer 2006, 6:23 http://www.biomedcentral.com/1471-2407/6/23
Page 3 of 7
(page number not for citation purposes)
of the results were confirmed by two independent RT-
PCRs.
Immunohistochemistry
Two-µm thick sections were cut and processed for immu-
nohistochemistry. After deparaffining and rehydration,
the sections were immersed in a bath (Dako, Milan, Italy)
for antigen retrieval for 45 min at 98°C in a freshly made
EDTA 1 mM solution, incubated with 3% H2O2 for 15
min, and then treated with primary antibodies raised
against Sp17 [monoclonal murine anti-Sp17 (Sp17MF1),
dilution 1:100 in phosphate buffered saline, PBS] at room
temperature for two hours, or with 1 mg /ml mouse IgG1
(Dako, Milan, Italy) as a negative control. This was fol-
lowed by 30 min incubation with the DAKO Envision sys-
tem (Dako, Milan, Italy). 3,3'-diaminobenzidine
tetrahydrochloride (Sigma Ltd, Missouri, USA) was used
as a chromogen to yield brown reaction products.
The testis specificity of the binding of the Sp17 antibodies
has been confirmed in competitive binding assays show-
ing the abrogation of testicular staining if the Sp17 anti-
bodies are pre-incubated with a very high concentration
(100 µg/ml) of soluble Sp17 recombinant protein [24].
The specificity of the primary antibodies raised against
Sp17 was also shown by Western blotting analyses
[17,18,25].
The nuclei were lightly counterstained with hematoxylin
solution (Medite, Bergamo, Italy).
The immunohistochemical reaction was observed using a
light microscope (Leica DMLA, Italy) at 40× and 100×
objective magnifications, and was semi-quantitatively
graded into four classes by two expert neuropathologists
on the basis of the frequency of Sp17 in NS cancer cells:
negative = no immunopositive cells (x); + = low frequency
(x ≤ 25%); ++ = moderate frequency (25% <x ≤ 50%); +++
= high frequency (50% <x ≤ 75%); ++++ = very high fre-
quency (75% <x ≤ 100%).
Statistical analysis
All of the data are expressed as mean values ± standard
deviation. The results were analysed using Statistica soft-
ware (StatSoft Inc., Tulsa, OK, USA). Univariate analysis
was performed by means of the Student t or chi-square
test as required for parametric and categorical variables. A
p value of less than 0.05 was considered to be statistically
significant.
Results
Patient baseline characteristics
Table 1 shows the investigated NS lesions and the
patients' baseline characteristics. Despite the limited
number of cases, the mean age of the patients with oli-
godendrogliomas (45 ± 10 years) was significantly differ-
ent from that of those with meningiomas (60 ± 14 years;
p = 0.03) or schwannomas (65 ± 9 years; p = 0.01). There
was no significance difference in gender distribution
between the neoplastic histological subtypes.
RT-PCR amplification of Sp17 mRNA
Using a pair of sequence-specific primers, mRNA encod-
ing Sp17 was found in testis, but not in brain, colon,
heart, liver, stomach, pancreas, and spleen (Fig. 1).
Table 1: Patient baseline characteristics.
Tumour histological subtype Patients (n) Age* (years) Sex
Astrocytoma 6 60 ± 20 4M/2F
Oligodendroglioma 5 45 ± 10 5M
Ependymoma 1 22 1F
Glioblastoma 16 59 ± 17 5M/11F
Meningioma 25 60 ± 14 8M/17F
Swhanoma 4 65 ± 9 3M/1F
Neurofibroma 1 32 1M
*Data are expressed as mean ± standard deviation
RT-PCR showing Sp17 transcripts in testis, but not in brain,  colon, heart, liver, stomach, pancreas, and spleen (a) Figure 1
RT-PCR showing Sp17 transcripts in testis, but not in brain, 
colon, heart, liver, stomach, pancreas, and spleen (a). Con-
trol amplification for the β-actin gene segment (b).BMC Cancer 2006, 6:23 http://www.biomedcentral.com/1471-2407/6/23
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Immunohistochemistry
Table 2 shows the frequencies of Sp17 expression at pro-
tein level. All three non-pathological NS specimens were
immunonegative (Fig. 2), but Sp17 was found in 21% of
the neuroectodermal and 4% of the meningeal lesions.
Excluding the only ependymoma (which was immunop-
ositive), the highest frequency was among the astrocyto-
mas. None of the nerve sheath tumours was
immunopositive. In all of the immunopositive lesions,
Sp17 was localised in the cytoplasm of a subset of cancer
cells. Each immunopositive case was semi-quantitatively
graded by two expert neuropathologists (Tab. 3). The
expression pattern was always heterogeneous (Fig. 3) and
did not correlate with the degree of malignancy.
Sp17 was expressed in six female patients, who accounted
for 86% of the immunopositive patients and one male.
Considering the presumed cell of origin of the lesions,
Sp17 was found in two females (100%) and no males
with astrocytoma; two females (18%) and one male
(20%) with glioblastoma; one female (5.8%) and no
males with meningioma; and one female (100%) with
ependymoma.
There was no difference in the mean age of the patients
who were Sp17 immunopositive or immunonegative.
Discussion
Despite advances in surgical techniques, imaging method-
ologies and adjuvant radiation therapy, the unfavourable
prognosis of most brain and other NS tumours [1-3] has
prompted an intensive search for effective treatment alter-
natives. Novel immunostimulatory strategies, such as
immunogenic therapy, directed cytokine delivery and
dendritic cell manipulation, have recently been used in
patients with malignant NS tumours in an attempt to
improve the results obtained with surgery, chemotherapy
and radiotherapy [7,8].
Since the first cloning of a human tumour antigen,
melanoma antigen-1 (MAGE-1), the identification of
tumour antigens capable of inducing an immune
response in cancer patients, and the development of vac-
cines targeting these antigens, have been formidable tasks
confronting tumour immunologists [5,6,9-13]. It has long
been accepted that immunotherapy is a powerful cancer
treatment, but it has been mainly limited by a poor under-
standing of the complexity of human beings, the immune
system, and highly intricate host-tumour interactions
[23,26].
The introduction of T-cell epitope cloning and, subse-
quently, a method based on the serological analysis of
recombinant tumour cDNA expression libraries using
autologous serum (SEREX), has led to the identification of
almost 44 CT gene families [10,11]. Sp17 has recently
been included among them because, although it was orig-
inally thought to be gamete-specific, it has also been iden-
Immunohistochemistry of Sp17 in nervous system neoplasms Figure 3
Immunohistochemistry of Sp17 in nervous system neo-
plasms: a-c. glioblastomas; d. astrocytoma; e. meningioma; f. 
ependimoma. In all cases, Sp 17 was localised in the cyto-
plasm of a few isolated and scattered tumoral cells. (a-d, 40× 
original magnification, 100× insets; e-f, 100× original magnifi-
cation).
Immunohistochemistry of Sp17 in non-pathological nervous  system tissues Figure 2
Immunohistochemistry of Sp17 in non-pathological nervous 
system tissues. There were no immunopositive cells (original 
magnification, 20×, 40× inset).BMC Cancer 2006, 6:23 http://www.biomedcentral.com/1471-2407/6/23
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tified in various human somatic and tumoral tissues [14-
16,18-20,27-29]. The expression frequencies of many CT
antigens have been determined in many neoplasms, but
little is known about their expression in human NS
tumours [11].
We show that Sp17 is heterogeneously expressed at pro-
tein level in a proportion of neuroectodermal and menin-
geal tumours, but not in nerve sheath neoplasms or non-
pathological NS tissues.
Sahin et al. (2000) have recently investigated the expres-
sion of seven CT genes (MAGE-3, NY-ESO-1, HOM-MEL-
40/SSX-2, SSX-1, SSX-4, HOM-TES-14/SCP-1, and HOM-
TES-85) in a series of human brain tumour specimens,
and concluded that a majority of oligoastrocytomas and
astrocytomas might be amenable to specific immuno-
therapeutic interventions, although the identification of
additional tumour-specific antigens frequently expressed
in gliomas should allow for the development of widely
applicable polyvalent glioma vaccines [30].
However, it must be pointed out that the authors investi-
gated mRNA expression, which does not necessarily corre-
late directly with protein expression. The discrepancies
between the frequencies of gene and protein expression
may reflect variations in tissue sampling, the heterogene-
ity tumour cells, or differences in the sensitivity of detec-
tion [10,11,26,31]. The expression of CT antigens in
clinical material has mainly been studied by RT-PCR at
gene expression level, but this approach is partially lim-
ited by the fact that it does not allow the quantification of
cancer cells positive for CT antigens [32]. On the contrary,
the availability of specific antibodies enables the recogni-
tion of candidate antigens in examined tissues, thus high-
lighting both the number and type of cells that are
immunopositive for a given antigen [11,23,32]; however,
the number of monoclonal antibodies against CT proteins
that can be used in immunohistochemical or biochemical
analyses of protein expression is still relatively limited
[11,32].
On the basis of our findings, it can be said that:
a. Sp17 can be recognised at protein level in various neu-
roectodermal and meningeal tumours, but not in nerve
sheath tumours.
b. Sp17 is localised in the cytoplasm of a variable number
of tumoral cells (Fig. 3). The focal expression of Sp17 in
NS cancer cells suggests that this antigen might not be suf-
ficient as a unique target for immunotherapeutic
approaches. It is now widely accepted that a prerequisite
for the success of any tumour-specific therapeutic strategy
is the existence and identification of antigen targets that
are not only exclusively or preferentially expressed in
malignant tissues, but also expressed in a high percentage
of neoplastic cells in a large number of patients [10-
12,23,31,33].
c. Although the clinical and patient characteristics of our
study population were similar to those described in other
series, its redistribution on the basis of immunohisto-
chemical findings highlights the fact that 86% of the sam-
ples immunopositive for Sp17 were taken from female
patients. Although this finding needs to be confirmed in a
large cohort of patients, it extends those of a previous
study by Takeoka et al. (2000), who found Sp17 expressed
in the synoviocytes of females with rheumatoid arthritis
[19].
The variable frequency of the expression of CT antigens,
and their uneven distribution in cancer cells [34], have
been recently been attributed to the spatial and temporal
Table 3: Semi-quantitative grading of Sp17 expression in NS 
tumours.
Sample Immunohistochemistry Pattern
Astrocytoma 1 +++ Cyto
Astrocytoma 2 +++ Cyto
Ependymoma ++ Cyto
Glioblastoma 1 ++ Cyto
Glioblastoma 2 +++ Cyto
Glioblastoma 3 +++ Cyto
Meningioma + Cyto
Notes: + = low frequency (x ≤ 25%) of cells immunopositive for 
Sp17; ++ = moderate frequency (25% < x ≤ 50%) of cells 
immunopositive for Sp17; +++ = high frequency (50% < x ≤ 75%) of 
cells immunopositive for Sp17; ++++ = very high frequency of cells 
immunopositive for Sp17 (75% < x ≤ 100%). Cyto = cytoplasmic Sp17 
localization.
Table 2: Sperm protein 17 expression frequencies in different 
histological subtypes of primary nervous system neoplasms. The 
lesions are categorised on the basis of their presumed cell of 
origin.
Cell of origin number positive/total number tested
Glial cell
Astrocytoma 2/6
Oligodendroglyoma 0/5
Ependymoma 1/1
Glioblastoma 3/16
Arachinodal cell
Meningioma 1/25
Nerve Sheath cell
Swhanoma 0/4
Neurofibroma 0/1BMC Cancer 2006, 6:23 http://www.biomedcentral.com/1471-2407/6/23
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complexity of tumoral lesions and their non-linear inter-
actions with the body environment [26,35-37]. These
basic characteristics have led to the development of a sys-
tem-level approach that is not only intended to generate a
human cancer map of the expression of candidate anti-
gens, but also to highlight common features underlying
tumours of unrelated histological origin, thus improving
our basic knowledge of tumour complexity [21].
Our study is the first to show the expression of Sp17 at
protein level in a proportion of NS tumours but not in
non-pathological NS tissues. This extends our knowledge
of CT antigens and NS cancer [38-41], and reinforces the
need for further studies aimed at clarifying the complex
function of Sp17, which clearly seems to go beyond the
simple role in the fertilisation process that was originally
attributed to it.
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